Merck & Co., Inc. (NYSE:MRK) Releases FY 2024 Earnings Guidance

Merck & Co., Inc. (NYSE:MRK) updated its FY 2024 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 8.530-8.650 for the period, compared to the consensus estimate of 8.560. The company issued revenue guidance of $63.1 billion-$64.3 billion, compared to the consensus revenue estimate of $63.8 billion. Merck & Co., Inc. also updated its FY24 guidance to $8.53-8.65 EPS.

Wall Street Analysts Forecast Growth

Several research firms recently commented on MRK. Truist Financial raised their price target on shares of Merck & Co., Inc. from $142.00 to $143.00 and gave the stock a buy rating in a report on Friday. Societe Generale cut shares of Merck & Co., Inc. from a hold rating to a sell rating and set a $104.00 price target for the company. in a report on Monday, March 11th. StockNews.com upgraded shares of Merck & Co., Inc. from a buy rating to a strong-buy rating in a report on Friday, February 2nd. TheStreet cut shares of Merck & Co., Inc. from a b+ rating to a c+ rating in a report on Monday, March 4th. Finally, Berenberg Bank raised their price target on shares of Merck & Co., Inc. from $140.00 to $143.00 and gave the stock a buy rating in a report on Monday, April 8th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of Moderate Buy and an average price target of $131.33.

Merck & Co., Inc. Stock Up 0.4 %

NYSE MRK traded up $0.48 during trading on Friday, reaching $131.20. The company’s stock had a trading volume of 7,757,091 shares, compared to its average volume of 8,336,531. The company has a current ratio of 1.25, a quick ratio of 1.00 and a debt-to-equity ratio of 0.89. The stock has a market capitalization of $332.33 billion, a PE ratio of 937.57, a PEG ratio of 1.65 and a beta of 0.38. The business has a 50-day moving average price of $126.34 and a 200-day moving average price of $115.69. Merck & Co., Inc. has a 1-year low of $99.14 and a 1-year high of $133.10.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings data on Thursday, April 25th. The company reported $2.07 earnings per share for the quarter, topping analysts’ consensus estimates of $1.94 by $0.13. Merck & Co., Inc. had a net margin of 0.61% and a return on equity of 9.33%. The business had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.21 billion. During the same period in the previous year, the company earned $1.40 earnings per share. Merck & Co., Inc.’s revenue for the quarter was up 8.9% on a year-over-year basis. On average, research analysts forecast that Merck & Co., Inc. will post 8.57 earnings per share for the current fiscal year.

Insider Transactions at Merck & Co., Inc.

In other news, insider Joseph Romanelli sold 1,000 shares of the business’s stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $124.89, for a total value of $124,890.00. Following the completion of the sale, the insider now directly owns 19,569 shares in the company, valued at $2,443,972.41. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, insider Joseph Romanelli sold 1,000 shares of the business’s stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $124.89, for a total transaction of $124,890.00. Following the transaction, the insider now owns 19,569 shares of the company’s stock, valued at $2,443,972.41. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Steven Mizell sold 50,694 shares of the business’s stock in a transaction on Friday, February 2nd. The stock was sold at an average price of $126.65, for a total transaction of $6,420,395.10. Following the transaction, the executive vice president now directly owns 23,619 shares in the company, valued at approximately $2,991,346.35. The disclosure for this sale can be found here. 0.09% of the stock is owned by corporate insiders.

Merck & Co., Inc. Company Profile

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.